[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Hospital Moinhos de Vento\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":187},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,50,76,101,129,155],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":32,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100607422","neuromuscular-electrical-stimulation-in-a-patient-on-invasive-mechanical-ventilation-movcare-100607422",false,"NCT07188350","Neuromuscular Electrical Stimulation in a Patient on Invasive Mechanical Ventilation (MOVCARE)","Neuromuscular Electrical Stimulation of Lower Limbs in Patients Undergoing Invasive Mechanical Ventilation: Randomized Clinical Trial","MOVCARE","Inclusion Criteria:\n\n* Patients will be eligible if they are 18 years or older, are under invasive mechanical ventilation (IMV), and are expected to require IMV for more than 48 hours.\n\nExclusion Criteria:\n\n* Body mass index (BMI) greater than or equal to 35 kg\u002Fm²;\n* Length of ICU stay longer than 7 ICU-free days or more than 3 continuous days of invasive mechanical ventilation (IMV) before enrollment;\n* Known intracranial process (e.g., stroke, intracranial hypertension);\n* Neuromuscular disease (e.g., Guillain-Barré syndrome, myasthenia gravis) at ICU admission;\n* Inability to speak Portuguese or pre-existing cognitive impairment prior to ICU admission;\n* Any condition that prevents neuromuscular electrical stimulation (NMES) treatment or assessment of the primary outcome in both legs (e.g., skin lesions, fractures, or amputation);\n* inability to transfer from bed to chair with or without assistance prior to hospital admission;\n* Cardiac arrest as the cause of ICU admission or cardiac arrest before screening;\n* Deep vein thrombosis (DVT) or pulmonary embolism (PE) treated for less than 48 hours;\n* Pregnant patients;\n* Known or suspected malignancy in the legs;\n* Any care limitation including a do-not-resuscitate order.","ALL","18 Years",{"count":20,"type":21},150,"ESTIMATED","INTERVENTIONAL",[24],"NA","This clinical study aims to compare the effects of conventional physical therapy alone versus conventional physical therapy combined with neuromuscular electrical stimulation (NMES) in patients admitted to the ICU and undergoing invasive mechanical ventilation. Participants will be randomly assigned to receive either conventional physical therapy or the same therapy plus NMES applied to the lower limbs. The protocol includes muscle-specific stimulation parameters and safety criteria to postpone sessions in cases of clinical instability. The primary goal is to assess whether NMES improves muscle function and recovery in critically ill patients.",[27,28,29,30,31],"Mechanical Ventilation","Critical Illness","Intensive Care Unit Patients","Muscle Weakness Condition","Neuromuscular Electrical Stimulation (NMES)",[33,34,27,35,36,28],"Neuromuscular Electrical Stimulation","Physiotherapy","Muscle Strength","Randomized Controlled Trial","RECRUITING","2026-03-22",{"date":40,"type":41},"2026-03-25","ACTUAL",{"date":43,"type":41},"2025-09-04",{"date":45,"type":21},"2027-03",{"name":47,"class":48},"Hospital Moinhos de Vento","OTHER",1,{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":54,"acronym":4,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":56,"targetDuration":4,"studyType":58,"phases":4,"briefSummary":59,"conditions":60,"keywords":63,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":75},"100462816","onco-genomas-brasil-mapping-breast-and-prostate-cancer-in-the-brazilian-public-health-system-100462816","NCT05306600","Onco-Genomas Brasil: Mapping Breast and Prostate Cancer in the Brazilian Public Health System","Inclusion criteria for breast cancer patients (Arm 1):\n\n* Women aged ≥ 18 years;\n* Brazilian nationality;\n* After review at the Hospital Moinhos de Vento, confirmed histological diagnosis of breast carcinoma with overexpression of HER2 (classified by immunohistochemistry as 3+ or 2+ with positive in-situ hybridization) or triple-negative (estrogen and progesterone receptors \\\u003C1% and no overexpression of HER2);\n* Clinical stage II or III for HER2-positive and I, II and III for triple-negative patients - American Joint Committee on Cancer (AJCC) 8th edition;\n* HER2- positive patients: must undergo neoadjuvant chemotherapy plus trastuzumab in the following regimens: anthracycline (doxorubicin or epirubicin) followed by taxane (docetaxel or paclitaxel), combined with trastuzumab, or a non-anthracycline option consisting of taxane (docetaxel or paclitaxel) combined with carboplatin and trastuzumab;\n* Triple-negative patients: must undergo neoadjuvant chemotherapy without immunotherapy in the following regimens: anthracycline (doxorubicin or epirubicin) followed by taxane (docetaxel or paclitaxel) with\u002F without platins (carboplatin ou cisplatin) or a regimen without anthracycline (taxane with\u002Fwithout platins)\n* Patients must provide written informed consent prior to inclusion\n\nInclusion criteria for patients with prostate cancer (Arm 2):\n\n* Men aged ≥ 18 years;\n* Confirmed histological diagnosis of prostate adenocarcinoma;\n* AJCC 8th edition clinical stage IV;\n* Patients must provide written informed consent.\n\nExclusion criteria for Arms 1 and 2:\n\n* No available paraffin-embedded tumor tissue for genomic analysis;\n* Inability to collect blood for genomic evaluation.",{"count":57,"type":21},882,"OBSERVATIONAL","This project aims to perform complete sequencing of the somatic (tumor) and germline exomes during clinical investigation of cancer patients treated through the Brazilian Unified Health System to generate genomic and phenotypic data for the Brazilian Ministry of Health's National Precision Genomics and Health Program, called Genomas Brasil, as well as to collect data on the population's ancestry.",[61,62],"Breast Cancer","Prostate Cancer",[64,65,66],"breast cancer","prostate cancer","exome","2026-02-12",{"date":69,"type":41},"2026-02-13",{"date":71,"type":41},"2022-11-09",{"date":73,"type":21},"2026-12-31",{"name":47,"class":48},25,{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":82,"eligibilityCriteria":83,"healthyVolunteers":84,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":85,"targetDuration":4,"studyType":58,"phases":4,"briefSummary":87,"conditions":88,"keywords":4,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":100},"100607281","genetic-variants-in-stroke-100607281","NCT07186517","Genetic Variants in Stroke","Assessment of Key Genetic vaRianTs and thEir iMpacts In Stroke","ÁRTEMIS-Brasil","Inclusion Criteria:\n\nCases\n\n* Age ≥18 years;\n* Confirmed diagnosis by neuroimaging (CT or MRI) of a first episode of ischemic stroke in the last 12 months;\n* TOAST classification of stroke available: cardioembolic, lacunar, atherosclerotic, or undetermined due to the presence of multiple sources (cardioembolic\u002Fatherosclerotic);\n* Modified Rankin Scale (mRS) ≤4 at the time of inclusion;\n* Ability and willingness to provide consent and participate in follow-up assessments.\n\nControls\n\n* Age ≥18 years;\n* Reside in the same household or, if not, in the same neighborhood as the case group participant;\n* Not be a blood relative of the case group participant;\n* Ability and willingness to provide consent and participate in follow-up assessments.\n\nExclusion Criteria:\n\nCases\n\n* Ischemic stroke with a distinct etiology based on TOAST criteria (e.g., infectious, autoimmune, endocarditis, reversible cerebral vasoconstriction syndrome, drug-related causes);\n* Diagnosis of monogenic or mitochondrial disorders, such as CADASIL, Fabry disease, homocystinuria, MELAS, sickle cell disease, among others;\n* Clinical conditions that reduce life expectancy to less than one year (e.g., neoplasia);\n* Inability to undergo magnetic resonance imaging (due to metal artifacts, MRI-incompatible implants, claustrophobia);\n* Other conditions that, at the investigator's discretion, prevent participation or compromise follow-up.\n\nControls\n\n* Personal history of stroke, transient ischemic attack (TIA), coronary, or peripheral artery disease;\n* Serious comorbidities that may impact participation or confound the results;\n* Clinical conditions that reduce life expectancy to less than one year;\n* Inability to provide consent due to cognitive impairment or other factors;\n* Inability to undergo magnetic resonance imaging (due to metal artifacts, incompatible implants, claustrophobia);\n* Diagnosis of monogenic or mitochondrial disorders, such as CADASIL, Fabry disease, homocystinuria, MELAS, or sickle cell disease;\n* Other conditions that, at the investigator's discretion, prevent participation or compromise follow-up.",true,{"count":86,"type":21},1000,"Stroke is the leading cause of death and disability in Brazil and worldwide, with a significant socioeconomic impact. Despite advances in prevention and treatment, the role of genetic variants in ischemic stroke remains underexplored, especially in genetically diverse populations like Brazil's. International studies such as MEGASTROKE and GIGASTROKE have identified risk loci for stroke, but with low representation of the Latin American population. This study aims to fill that gap by evaluating the prevalence and clinical impact of genetic polymorphisms previously described in Brazilians, thereby laying the groundwork for precision medicine within Brazil's Unified Health System (SUS).",[89,90],"Stroke","Genetic Association Studies","NOT_YET_RECRUITING","2025-09-15",{"date":94,"type":41},"2025-09-22",{"date":96,"type":21},"2025-10-01",{"date":98,"type":21},"2030-12-31",{"name":47,"class":48},11,{"id":102,"slug":103,"hasResults":11,"nctId":104,"briefTitle":105,"officialTitle":106,"acronym":107,"eligibilityCriteria":108,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":109,"targetDuration":4,"studyType":22,"phases":111,"briefSummary":113,"conditions":114,"keywords":116,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":121,"startDateStruct":123,"completionDateStruct":125,"leadSponsor":127,"locationsCount":128},"100454601","phase-3-randomization-to-extend-stroke-intravenous-thrombolysis-in-evolving-non-large-vessel-occlusion-with-tnk-resilient-100454601","NCT05199662","Randomization to Extend Stroke Intravenous ThromboLysis In Evolving Non-Large Vessel Occlusion With TNK (RESILIENT","A Phase III, Randomized, Multi-center Clinical Trial That Will Examine Whether Treatment With Intravenous TNK is Superior to Placebo in Patients Who Suffer a Non-large Vessel Occlusion Ischemic Stroke Within 4.5-12 Hours From Time Last Seen Well","EXTEND-IV","Inclusion Criteria:\n\n1. Acute ischemic stroke where patient is ineligible for IV thrombolytic treatment with Alteplase due to onset \\>4.5 hours and is ineligible for endovascular treatment under standard of care due to absence of proximal arterial occlusion (e.g. intracranial ICA, MCA-M1 and dominant M2 segments, and vertebrobasilar arteries).\n\n   \\* Dominant M2 segment is defined is a division supplying \\>50% of the MCA territory vs co-dominant supplying 50% of the MCA territory vs non-dominant supplying \\\u003C50% of the MCA territory.\n2. No significant pre-stroke functional disability (mRS ≤2).\n3. Age ≥18 years (no upper age limit).\n4. Clinical or imaging mismatch evidence in distal artery territories, defined as one of the following scenarios (A, B or C):\n\n   * Scenario A - all of the following:\n\n     * Significant cortical neurological deficit (moderate to severe afasia, moderate to severe heminegligence, severe hemianopsia) with the addition or not of motor symptoms OR any motor deficit accompanied of cortical symptoms of any severity;\n     * Contrast-enhanced CT of the head or head MRI with \\\u003C50% involvement of the vascular territory corresponding to the clinical manifestation;\n     * Arterial head angiotomography or arterial head angioMRI WITHOUT proximal intracranial artery occlusion that would require endovascular therapy (for example, ICA intracranial, MCA-M1 and M2 dominant segments and vertebral and basilar arteries)\n   * Scenario B - all of the following:\n\n     * NIHSS score ≥ 4 due to any neurologic deficits;\n     * Non-contrast CT of the head or head MRI com \\\u003C50% involvement of the vascular territory corresponding to the clinical manifestation;\n     * Arterial head angioCT or arterial head MRI WITHOUT proximal intracranial artery occlusion that would require endovascular therapy (for example, ICA intracranial, MCA-M1 and M2 dominant segments and vertebral and basilar arteries)\n     * Arterial head angioCT with distal occlusion on MIP or wedge-shaped lesion on parenchymography on the source-image of angiotomography OR CT perfusion with wedge-shaped cortical lesion.\n   * Scenario C - all of the following:\n\n     * NIHSS score ≥ 4 due to any neurologic deficits;\n     * The presence of a Target Mismatch defined as:\n\n       * Ischemic Core \\\u003C50cc (defined on NCCT\u002FCTP\\* or DWI MRI) \\*Volume NCCT can be used to exclude patients if the investigator believes that its volume assessment is more reliable that the CTP in any particular case.\n       * Mismatch Volume (Tmax \\>6sec lesion - Core volume lesion) \\>10cc\n       * Mismatch Ratio \\>1.4\n5. Patient treatable within 4.5-12 hours of symptom onset. Symptoms onset is defined as point in time the patient was last seen well (at baseline). Treatment start is defined as initiation of IV TNK or placebo infusion.\n\n   * Patients who have woken up with the symptoms and don't have a mismatch FLAIR-DWI according to the WAKE-UP Trial image criteria will have their window considered to be \\>4.5 hours. In this case, the time last seen well must have been 12 hours at most.\n6. Informed consent obtained from patient or acceptable patient surrogate.\n\nExclusion Criteria:\n\n1. Intracranial hemorrhage (ICH) identified by CT or MRI.\n2. Rapidly improving symptoms, particularly if in the judgment of the managing clinician that the improvement is likely to result in the patient without eligibility criteria.\n3. Pre-stroke mRS score of ≥ 2 (indicating previous disability)\n4. Contra indication to imaging with MR or CT with contrast agents.\n5. Infarct core \\>1\u002F3 MCA territory qualitatively or \\>50 mL quantitatively (determined by DWI lesion on MR).\n6. Participation in any investigational study in the previous 30 days\n7. Any terminal illness such that patient would not be expected to survive more than 1 year).\n8. Baseline platelet count \\\u003C 100.000\u002FµL\n9. Woman of childbearing potential who is known to be pregnant or who has a positive pregnancy test on admission.\n10. Previous stroke within last three months.\n11. Recent past history or clinical presentation of ICH, subarachnoid hemorrhage (SAH), arterio-venous (AV) malformation, aneurysm, or cerebral neoplasm other than meningioma.\n12. Current use of oral anticoagulants and a prolonged prothrombin time (INR \\> 1.6).\n13. Use of heparin, except for low dose subcutaneous heparin, in the previous 48 hours and a prolonged partial thromboplastin time exceeding the upper limit of the local laboratory normal range\n14. Use of glycoprotein IIb - IIIa inhibitors within the past 72 hours. Use of single agent oral platelet inhibitors (clopidogrel or low-dose aspirin) prior to study entry is permitted.\n15. Clinically significant hypoglycemia.\n16. Uncontrolled hypertension defined by a blood pressure \\> 185 mmHg systolic or \\>110 mmHg diastolic on at least 2 separate occasions at least 10 minutes apart, or requiring aggressive treatment to reduce the blood pressure to within these limits. The definition of \"aggressive treatment\" is left to the discretion of the responsible Investigator.\n17. Hereditary or acquired hemorrhagic diathesis.\n18. Gastrointestinal or urinary bleeding within the preceding 21 days.\n19. Major surgery within the preceding 14 days which poses risk in the opinion of the Investigator.\n20. Exposure to a thrombolytic agent within the previous 72 hours.\n21. Subject participating in a study involving an investigational drug or device that would impact this study.",{"count":110,"type":21},466,[112],"PHASE3","A phase III, randomized, multi-center clinical trial that will examine whether treatment with intravenous TNK is superior to placebo in patients who suffer a non-large vessel occlusion ischemic stroke within 4.5-12 hours from time last seen well. The randomization employs a 1:1 ratio of intravenous thrombolysis with Tenecteplase (TNK) versus placebo in patients who suffer a non-large vessel occlusion ischemic stroke between 4.5 and 12 hours from time last seen well (TLSW) and with a clinical-radiological mismatch or evidence of salvageable brain tissue on perfusion imaging.",[115],"Ischemic Stroke, Acute",[117,118,119],"Ischemic Stroke","Thrombolysis","Tenecteplase","2025-04-02",{"date":122,"type":41},"2025-04-04",{"date":124,"type":41},"2022-01-20",{"date":126,"type":21},"2027-07",{"name":47,"class":48},15,{"id":130,"slug":131,"hasResults":11,"nctId":132,"briefTitle":133,"officialTitle":134,"acronym":135,"eligibilityCriteria":136,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":137,"enrollmentInfo":138,"targetDuration":4,"studyType":22,"phases":140,"briefSummary":141,"conditions":142,"keywords":145,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":149,"startDateStruct":150,"completionDateStruct":152,"leadSponsor":153,"locationsCount":154},"100454565","phase-3-randomization-to-endovascular-treatment-alone-or-preceded-by-systemic-thrombolysis-with-tenecteplase-in-ischemic-stroke-100454565","NCT05199194","Randomization to Endovascular Treatment Alone or Preceded by Systemic Thrombolysis With Tenecteplase in Ischemic Stroke","Randomization to EndoVascular Treatment Alone or Preceded by Systemic Thrombolysis With Tenecteplase in Acute Ischemic Stroke Due to Large Intracranial VEssel OcclusioN Trial - DIRECT Thrombectomy vs. Intravenous TNK Plus Thrombectomy","DIRECT-TNK","Inclusion Criteria:\n\n* Acute ischemic stroke where a patient is eligible for IV thrombolytic treatment within 4.5 hours of stroke onset.\n* No significant pre-stroke functional disability (mRS ≤ 1)\n* Baseline NIHSS scores obtained before randomization must be equal to or higher than 6 points\n* Age equal ≥ 18 and =\\\u003C 85 years\n* Occlusion (TICI 0-1) of the ICA or proximal MCA segments (M1 or M2) suitable for endovascular treatment, as evidenced by CTA, MRA, or angiogram, with or without concomitant cervical carotid stenosis or occlusion.\n* Patient randomized within 4.5 hours of symptom onset. Symptoms onset is defined as the point in time the patient was last seen well (at baseline). Treatment start is defined as groin puncture, max 90 minutes after randomization.\n\n  * Patients who have woken up with the symptoms and who have a mismatch FLAIR-DWI according to the WAKE-UP Trial will be considered as having a time window of \\\u003C4.5h.\n* Informed consent obtained from the patient or acceptable patient surrogate.\n\nExclusion Criteria:\n\n* Known hemorrhagic diathesis, coagulation factor deficiency, or oral anticoagulant therapy with INR \\> 1.7 or direct oral anticoagulants such as thrombin antagonists (ex: dabigatran) or X factor (ex: rivaroxaban, apixaban, edoxaban) at the least 48 hours.\n* Baseline platelet count \\\u003C 100.000\u002FμL\n* Baseline blood glucose of \\\u003C 50mg\u002FdL or \\> 400mg\u002Fdl\n* Severe, sustained hypertension (SBP \\> 185 mm Hg or DBP \\> 110 mm Hg) NOTE: If the blood pressure can be successfully reduced and maintained at the acceptable level using AHA guidelines recommended medication (including iv antihypertensive drips), the patient can be enrolled.\n* Patients in coma (NIHSS item of consciousness \\>1) (Intubated patients for transfer could be randomized only in case an NIHSS is obtained by a neurologist prior transportation).\n* Seizures at stroke onset which would preclude obtaining a baseline NIHSS\n* Serious, advanced, or terminal illness with anticipated life expectancy of less than one year.\n* History of life-threatening allergy (more than rash) to contrast medium.\n* Subjects who has received IV t-PA treatment before the randomization.\n* Renal failure with serum creatinine ≥ 3 mg\u002Fdl\n* Woman of childbearing potential who is known to be pregnant or who has a positive pregnancy test on admission.\n* Subject participating in a study involving an investigational drug or device that would impact this study.\n* Cerebral vasculitis, endocarditis or subarachnoid hemorrhage.\n* Patients with a pre-existing neurological or psychiatric disease that would confound the neurological or functional evaluations.\n* Unlikely to be available for 90-day follow-up (e.g. no fixed home address, visitor from overseas).\n* Hypodensity on CT more than one third of MCA territory or hypersignal in more than one third of MCA territory on MR-DWI.\n* ASPECTS score \\\u003C 6 (no contrast at least 5 mm cut imaging on CT) or on MR-DWI sequence.\n* CT or MR evidence of hemorrhage (the presence of \\\u003C 5 GRE, SWI, SWAN microbleeds is allowed).\n* Significant mass effect with midline shift.\n* Evidence of ipsilateral carotid occlusion, high grade stenosis or arterial dissection in the extracranial or petrous segment of the internal carotid artery that cannot be treated or will prevent access to the intracranial clot or excessive tortuosity of cervical vessels precluding device delivery\u002Fdeployment.\n* Subjects with occlusions in multiple vascular territories (e.g., bilateral anterior circulation, or anterior\u002Fposterior circulation).\n* Evidence of intracranial tumor (except small meningioma).","85 Years",{"count":139,"type":21},398,[112],"A phase III randomized, multi-center, double-blinded, placebo-controlled clinical trial that will examine two strategies for the treatment of acute ischemic stroke associated with a large vessel anterior occlusion within 4.5 hours from symptoms onset: direct endovascular treatment vs. endovascular treatment preceded by intravenous tenecteplase.",[143,144],"Stroke, Ischemic","Stroke, Acute",[119,146,147,148],"TNK","MT","Mechanical Thrombectomy",{"date":122,"type":41},{"date":151,"type":41},"2022-05-27",{"date":126,"type":21},{"name":47,"class":48},13,{"id":156,"slug":157,"hasResults":11,"nctId":158,"briefTitle":159,"officialTitle":160,"acronym":161,"eligibilityCriteria":162,"healthyVolunteers":11,"sex":17,"minAge":163,"maxAge":164,"enrollmentInfo":165,"targetDuration":4,"studyType":22,"phases":167,"briefSummary":168,"conditions":169,"keywords":171,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":178,"lastUpdatePostDateStruct":179,"startDateStruct":181,"completionDateStruct":183,"leadSponsor":185,"locationsCount":186},"100451179","phase-3-polypill-and-riscometer-to-prevent-stroke-and-cognitive-impairment-promote-100451179","NCT05155137","Polypill and RiscOMeter to Prevent StrOke and CogniTive ImpairmEnt (PROMOTE)","Polypill and RiscOMeter to Prevent StrOke and CogniTive ImpairmEnt in Primary Health Care","PROMOTE","Inclusion Criteria:\n\n* adults aged 50-75 years;\n* no previous history of stroke, TIA or cardiovascular disease;\n* systolic blood pressure (SBP) 121-139 mmHg;\n* with one or more lifestyle risk factors: smoking, overweight (BMI\\> 25 kg \u002F m2), physical inactivity (WHO criteria for aerobic physical activity \\\u003C150 minutes \u002F week or at least 75 minutes of aerobic physical activity of vigorous intensity during the week or an equivalent combination of activity of moderate and vigorous intensity) or inadequate diet \u002F poor eating habits (low intake of fruits and vegetables, fish, whole grains, high intake of drinks sweetened with sodium and sugar)\n* owns or has access to a cell phone that can receive text messages.\n\nExclusion Criteria:\n\n* Diagnostic of hypercholesterolemia (\\> 190mg\u002FdL LDL cholesterol) or diabetes or take other antihypertensive drugs or open label statins;\n* Contraindication to the medication\n* Life expectancy \\\u003C 5 years\n* Participation in another clinical trial","50 Years","75 Years",{"count":166,"type":21},8518,[112],"This study is a phase III, prospective, placebo-controlled randomized clinical trial involving 8,518 subjects with low to moderate stroke risk, followed for 3 years in Brazil. Participants will be randomized to receive either the polypill (valsartan 80 mg, amlodipine 5 mg, and rosuvastatin 10 mg), with dose adjustment of amlodipine to 2.5 mg for patients experiencing adverse events, or a placebo, and to either use the Stroke Riskometer for lifestyle modification or receive usual care. The purpose of the study is to test whether the polypill, alone or in combination with lifestyle modification, will reduce the incidence of stroke and cognitive impairment in this population.",[89,170],"Cognitive Decline",[172,173,174,175,176,177],"stroke","cognitive decline","prevention","polypill","stroke riskometer","primary care","2025-01-20",{"date":180,"type":41},"2025-01-23",{"date":182,"type":41},"2021-12-20",{"date":184,"type":21},"2030-12-14",{"name":47,"class":48},2,""]